Chlorin e6 (Synonyms: Ce6) |
Catalog No.GC43244
One-Click Copy Product Info
|
Chlorin e6, a photosensitizer with a simple porphyrin nucleus, has strong absorption peaks at wavelengths of 403nm and 664nm.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 19660-77-6
Sample solution is provided at 25 µL, 10mM.
Chlorin e6, a photosensitizer with a simple porphyrin nucleus, has strong absorption peaks at wavelengths of 403nm and 664nm[1]. Chlorin e6 exhibits low dark toxicity, high phototoxicity, and rapid accumulation in target tissues, enabling the generation of singlet oxygen and the formation of intracellular reactive oxygen species (ROS)[2]. Chlorin e6 has been widely used in photodynamic therapy and dynamic acoustic therapy to inhibit tumor growth and regulate bacterial activity[3].
In vitro, Chlorin e6 treatment for 48 hours significantly inhibited the viability of HepG2 and B16-F10 cells, with IC50 values of 1.66µM and 1.67µM, respectively, under 10J/cm2 irradiation (24h)[4]. Chlorin e6 (0.2mg/ml) treatment for 45 minutes combined with 1.0MHz/cm2 ultrasound (60s) induced G2/M phase arrest and apoptosis in SPCA-1 cells[5]. Pretreatment with 170µM Chlorin e6 for 90 minutes, followed by irradiation at 2J/cm2, induced vascular smooth muscle cell death, accompanied by DNA fragmentation, reduced cell membrane polarization, and caspase-3 activation[6].
In vivo, oral administration of Chlorin e6 at a dose of 5mg/kg every 2 days, combined with 4.96mW/cm2 light irradiation for 4 weeks, significantly attenuated high-fat diet-induced obesity, reduced hepatic lipid accumulation, and decreased epididymal adipocyte size in mice[7].
References:
[1] Paul S, Heng P W S, Chan L W. Optimization in solvent selection for chlorin e6 in photodynamic therapy[J]. Journal of fluorescence, 2013, 23(2): 283-291.
[2] Pandit R P, Thapa Magar T B, Shrestha R, et al. Isolation, identification, and biological activities of a new chlorin e6 derivative[J]. International Journal of Molecular Sciences, 2024, 25(13): 7114.
[3] Liao S, Cai M, Zhu R, et al. Antitumor effect of photodynamic therapy/sonodynamic therapy/sono-photodynamic therapy of chlorin e6 and other applications[J]. Molecular pharmaceutics, 2023, 20(2): 875-885.
[4] Huang F, Li Y, Zhang X J, et al. Novel chlorin e6-based conjugates of tyrosine kinase inhibitors: Synthesis and photobiological evaluation as potent photosensitizers for photodynamic therapy[J]. European Journal of Medicinal Chemistry, 2023, 261: 115787.
[5] Chen B, Zheng R, Liu D, et al. The tumor affinity of chlorin e6 and its sonodynamic effects on non-small cell lung cancer[J]. Ultrasonics sonochemistry, 2013, 20(2): 667-673.
[6] Wawrzyńska M, Kałas W, Biały D, et al. In vitro photodynamic therapy with chlorin e6 leads to apoptosis of human vascular smooth muscle cells[J]. Archivum Immunologiae et Therapiae Experimentalis, 2010, 58(1): 67-75.
[7] Shrestha R, Gurung P, Lim J, et al. Anti-obesity effect of Chlorin e6-mediated photodynamic therapy on mice with high-fat-diet-induced obesity[J]. Pharmaceuticals, 2023, 16(7): 1053.
| Cell experiment [1]: | |
|
Cell lines |
B16-F10 cells |
|
Preparation Method |
B16-F10 cells were cultured in RPMI-1640 medium, supplemented with 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin, at 37°C in an incubator with 5% CO2. Cells were seeded into 96-well plates at a density of 5×103 cells/ml and incubated for 24h at 37°C. Cells were exposed to gradient concentrations of Chlorin e6 (0, 0.1, 1, 10, and 100µM) for 48h, cell viability was measured. |
|
Reaction Conditions |
0, 0.1, 1, 10, and 100µM; 48h |
|
Applications |
Chlorin e6 treatment reduced cell viability in B16-F10 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL6 mice |
|
Preparation Method |
Male C57BL6 mice (4 weeks old) were housed and maintained in a standard environment (room temperature 20±2°C; humidity 50±5%; light/dark cycle: 12:12h) in the standard lab facility for a week. The mice were randomly divided into 3 groups with similar weights: normal group (Nor), vehicle-treated high-fat diet group (HFD), high-fat diet with Chlorin e6 (5mg/kg) and light of a high fluence rate (4.96mW/cm2). The normal group of mice was fed a normal diet (10% fat), while the remaining groups were fed a high-fat diet (60% fat) for 70 days to increase the body weight by about 70%. Chlorin e6 (5mg/kg/day) was dissolved in normal saline, filtered through a 0.2µm syringe filter, and administered orally to the treated mice every two days with 4.96mW/cm2 light for 4 weeks. The weight changes in mice, along with food and water intake, were measured every week. |
|
Dosage form |
5mg/kg; every two days; 4 weeks; p.o. |
|
Applications |
Chlorin e6 treatment combined with 4.96mW/cm2 light decreased body weight in mice with a high-fat diet. |
References: [1] Huang F, Li Y, Zhang X J, et al. Novel chlorin e6-based conjugates of tyrosine kinase inhibitors: Synthesis and photobiological evaluation as potent photosensitizers for photodynamic therapy[J]. European Journal of Medicinal Chemistry, 2023, 261: 115787. [2] Shrestha R, Gurung P, Lim J, et al. Anti-obesity effect of Chlorin e6-mediated photodynamic therapy on mice with high-fat-diet-induced obesity[J]. Pharmaceuticals, 2023, 16(7): 1053. | |
| Cas No. | 19660-77-6 | SDF | |
| Synonyms | Ce6 | ||
| Chemical Name | (7S,8S)-3-carboxy-5-(carboxymethyl)-13-ethenyl-18-ethyl-7,8-dihydro-2,8,12,17-tetramethyl-21H,23H-porphine-7-propanoic acid | ||
| Canonical SMILES | CC1=C2[NH]C(/C(CC(O)=O)=C([C@@H](CCC(O)=O)[C@@H]3C)\[N]=C3/C=C4[NH]/C(C(C=C)=C\4C)=C\C5=[N]/C(C(CC)=C5C)=C\2)=C1C(O)=O | ||
| Formula | C34H36N4O6 | M.Wt | 596.7 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:6): 0.14 mg/ml,Ethanol: slightly soluble | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6759 mL | 8.3794 mL | 16.7588 mL |
| 5 mM | 335.2 μL | 1.6759 mL | 3.3518 mL |
| 10 mM | 167.6 μL | 837.9 μL | 1.6759 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >90.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
The anti-lung cancer efect of HTS NPs in vivo. (C-D)The fuorescence intensity was cal-culated and analyzed based on the data in (B).
To examine the targeting properties of NPs, 2mg HT-Ce6 NPs were intravenously injected in mice with the equal mass of T-Ce6 NPs (2mg) and Ce6 (2mg) (GLPBIO, USA) used as controls.
J Exp Clin Canc Res, 2023, 42(1): 188. PMID: 37507782 IF: 11.2997 -
Related Biological Data
B Bioluminescence images of tumor-bearing BALB/c mice at diferent time points after intravenous injection with Ce6, ZIF-8@Gem/D-1-MT/Ce6 NPs, and HA/ZIF-8@Gem/D-1-MT/Ce6 NPs.
For bioluminescent imaging, 40mg of Ce6 (GLPBIO, USA), 40mg of Gem and 40mg of D-1-MT was dissolved in 4mL THF (50%) as solution D, which was sequentially stirred with solution B and solution C for 15min.
J Exp Clin Canc Res 41.1 (2022): 1-17. PMID: 35501823 IF: 11.1613 -
Related Biological Data
Cytotoxicity of A-C/NPs in breast cancer. (A) Cell viability of 4T1, breast cancer cells co-cultured with free Ara-C, Ce6, and A-C/NPs with or without NIR laser irradiation.
The mice were injected with free Ce6 (2mg/kg Ce6) or A-C/NPs (2mg/kg Ce6(GLPBIO, USA)) via the tail vein.
Acs Appl Mater Inter 15.1 (2022): 452-468. PMID: 36538368 IF: 9.4998 -
Related Biological Data
Cellular uptake and in vitro phototoxicity of BCT NPs. (C) Fluorescent uptake images of DLD-1 cells incubated with the indicated formulations.
Free Ce6 and BCT NPs were systemically administered to the mice through the tail vein at a dose of Ce6 (GLPBIO, USA) 3mg kg−1.
Materials & Design (2023): 111613. IF: 9.4167
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)